IL-ZS
The global professional services firm ZS announced today that it has acquired Danish bioinformatics and systems biology company, Intomics . Founded in Copenhagen, Denmark in 2008, Intomics accelerates and optimizes pharmaceutical drug discovery and development by enabling complex analysis of biomedical data. The addition of renowned scientists to the ZS team will strengthen ZS’s focus on the discovery of new medicines for all.
Global pharmaceutical and biotech companies, along with other biomedical research entities, use Intomics’s service and technology offerings to assist in preclinical work, including target discovery, biomarker identification, drug repositioning and patient stratification. As the pharmaceutical industry intensifies its efforts on developing novel drugs, demand for innovative capabilities in discovery and disease biology is growing.
Intomics’s highly curated and best-in-class protein-protein interaction network is condition-agnostic and supports tailored biomedical analysis spanning multiple diseases. Scientists and bioinformaticians use the network to understand disease biology at the pathway and molecular level. This drives novel insights and discoveries and accelerates preclinical activities to ultimately bring new medicines to patients faster.
“Our strategic acquisition of Intomics will allow us to assist our clients in pursuing breakthrough science and innovative medicines that profoundly improve patients’ lives,” said Pratap Khedkar, CEO of ZS. “Combined, our unique mix of deep data, academic and scientific expertise, technology and artificial intelligence will ultimately accelerate drug discovery and improve the probability of success for innovative medicines.”
The 42 members of Intomics will join ZS’s staff of 12,000 employees worldwide and strengthen its team of molecular natives who combine scientific, data science and technology expertise with a research mindset to advance the adoption of in-silico methods in drug discovery. The addition of Intomics expands upon ZS’s existing data and technology offerings to bring further sophistication in leveraging analytics, bioinformatics and applied mathematics to drive business impact for the science of R&D.
“For us, ZS was a natural destination to build on our legacy. Through integration with ZS, we will be able to broaden our impact in drug discovery, increase the scale and use of AI in our client work and operate on a global scale while expanding career opportunities for our team members,” said Thomas S. Jensen, Ph.D., CEO and co-founder of Intomics. “Our shared roots in academia and shared values, including a commitment to rigor, a deliberative approach and doing right by both our clients and our staff, made ZS a natural fit for us and for our clients,” he continued.
About ZS
ZS is a professional services firm that works side by side with companies to help develop and deliver products that drive customer value and company results. We leverage our deep industry expertise, leading-edge analytics, technology and strategy to create solutions that work in the real world. With more than 37 years of experience and 12,000-plus ZSers in 30-plus offices worldwide, we’re passionately committed to helping companies and their customers thrive. To learn more, visit www.zs.com or follow us on Twitter and LinkedIn .
About Intomics
Intomics was founded by world-leading scientists within the field of bioinformatics and systems biology to accelerate and improve drug discovery and development. We are biologists, bioinformaticians, data scientists and software engineers who share a passion for translating data to cures. And we’ve proudly done so for more than 10 years. We collaborate closely with our clients in the biotech and pharmaceutical industry, and we harness the synergy between our clients’ specific disease knowledge and our unique data analytics expertise and technology. Together we make a difference for patients. This is both our trademark and what drives the people of Intomics.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220504005267/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Logical Intelligence Introduces First Energy-Based Reasoning AI Model, Signals Early Steps Toward AGI, Adds Yann LeCun and Patrick Hillmann to Leadership21.1.2026 19:21:00 CET | Press release
Logical Intelligence, an artificial intelligence company developing energy-based (EBM) reasoning systems, today announced that Kona 1.0, its pioneering EBM for reasoning, will enter pilot programs with select partners in the energy, advanced manufacturing, and semiconductor industries later this quarter. Logical Intelligence also released a live demonstration of Kona 1.0 on its website, beginning with head-to-head sudoku challenges against leading large language models. Additional demonstrations, including chess and Go, are planned. The company said the goal is to give researchers and the public a clear view into how energy-based reasoning differs from probabilistic systems. “Kona learns by recognizing and correcting its own mistakes, rather than guessing the most likely answer,” said Eve Bodnia, founder and CEO of Logical Intelligence. “If general intelligence means the ability to reason across domains, learn from error, and improve without being retrained for each task, then we are s
Galderma Provides Update on Arbitration Case Regarding Neuromodulator Research and Development Partnership21.1.2026 17:35:00 CET | Press release
Galderma (SIX:GALD), the pure-play dermatology category leader, today announced that an International Chamber of Commerce arbitral tribunal issued an award confirming the termination of a 2014 neuromodulator research & development partnership with Ipsen. The partnership was limited to the rights and obligations relating to the companies’ early-stage neuromodulator pipeline for aesthetic indications. Galderma welcomes the clarity provided by the arbitral tribunal. This decision has no impact on the commercialization of Galderma’s neuromodulator portfolio. Galderma will continue to commercialize and supply Dysport®/Azzalure®, Alluzience®, and RelfydessTM in all territories where it has regulatory approval and in accordance with our existing agreements with our partner Ipsen. Progressing on our path towards becoming the undisputed dermatology powerhouse Galderma remains focused on its ambition to become the world’s undisputed dermatology powerhouse across the full spectrum of a fast-growi
ThetaRay Appoints Financial Markets Technology Leader Brad Levy as Chief Executive Officer21.1.2026 17:00:00 CET | Press release
Former Symphony CEO to lead ThetaRay’s next phase of AI-driven category leadership in transaction monitoring and due diligence ThetaRay, a global leader in Cognitive AI financial crime compliance, today announced the appointment of Brad Levy as Chief Executive Officer. Levy, a leading financial markets infrastructure executive and former CEO of Symphony, will lead ThetaRay’s next phase of growth as the company continues to scale its Cognitive AI platform, now emerging as the leading AI strategy and technology for transaction monitoring and transaction due diligence, across banks and fintechs worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121002476/en/ ThetaRay Appoints Brad Levy as CEO Levy brings decades of experience building and leading mission-critical financial infrastructure at scale. Most recently, he served as CEO of Symphony, the financial markets infrastructure and technology platform established by a
HCL Group and UpLink Announce Winners of ‘Water Resilience Challenge’ Under the Aquapreneur Innovation Initiative21.1.2026 16:02:00 CET | Press release
10 Aquapreneurs selected from over 300 applicantsWinners showcased innovations across digital water management, biological breakthroughs, hardware solutions, deep-tech design, and community-driven modelsFinancial support of CHF 1.75 million available to scale initiativesAquapreneur Innovation Initiative: CHF 15 million commitment to global water challenges HCL Group, a leading global conglomerate, and UpLink, the World Economic Forum’s early-stage innovation initiative, have announced the winners of the ‘Water Resilience Challenge,’ the fourth in a series of five challenges under the five-year, CHF 15 million Aquapreneur Innovation Initiative launched by HCL Group. The announcement marks a significant step in the ongoing mission to address global water challenges through innovation and entrepreneurship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260121697759/en/ Roshni Nadar Malhotra, Chairperson of HCL Group, congratula
illumynt Appoints Chris Tejeda as Chief Revenue Officer21.1.2026 15:47:00 CET | Press release
illumynt today announced the promotion of Chris Tejeda to Chief Revenue Officer (CRO), reflecting the company’s continued growth and expanding global footprint. In his new role, Tejeda will lead illumynt’s global revenue strategy, customer engagement, and strategic partnerships as demand accelerates for secure, technology-driven IT Asset Disposition (ITAD) solutions. “Chris has been instrumental in aligning our commercial strategy with the evolving needs of hyperscale and enterprise customers,” said CEO Joerg Herbarth. “As AI accelerates infrastructure refresh cycles and raises the bar for security and compliance, his leadership will be critical to scaling illumynt with focus, transparency, and customer trust.” Tejeda brings extensive experience in enterprise technology services and has played a key role in illumynt’s recent momentum, including significant revenue growth and the expansion of advanced capabilities across AI/GPU diagnostics, automation, and value recovery. View source ve
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom